Roche CEO Severin Schwan (AP Images)

Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

De­spite its stand­ing as phar­ma’s biggest can­cer play­er, Roche has most­ly stood pat on next-gen cell ther­a­pies that its com­peti­tors have gob­bled up with gus­to. Ready to fi­nal­ly make a splash of its own, Roche has inked a ma­jor deal to dive in­to the fu­ture.

Roche’s Genen­tech has signed a deal worth $150 mil­lion up­front and a to­tal val­ue of more than $3 bil­lion to part­ner with Adap­ti­m­mune on off-the-shelf T cell ther­a­pies that marks the can­cer gi­ant’s first sig­nif­i­cant pipeline piv­ot in­to next-gen on­col­o­gy drugs, the part­ners said Tues­day.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters